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Abstract
Cholesterol homeostasis is tightly regulated by a group of endocrine hormones under 
physiological conditions. Hormonal dysregulation is often associated with disturbed 
cholesterol homeostasis, resulting in many clinical disorders including atherosclerosis, 
fatty liver and metabolic syndrome. Circulating hormones regulate cholesterol metabo-
lism by altering levels of relative genes either through their interactions with nuclear 
receptors or by interfering with bile acid signaling pathways. A better understanding of 
hormonal regulation of cholesterol metabolism would improve our likelihood of identi-
fying effective and selective targets for the intervention of disturbed cholesterol. In this 
review, we discuss selected hormones critical for the cholesterol balance, including thy-
roid hormone, sex hormones, growth hormone, glucagon and irisin. We focus our discus-
sion on the most recent advance in clinical epidemiology, animal mechanistic studies and 
the clinical application.
Keywords: cholesterol, thyroid hormone, sex hormones, growth hormone, glucagon 
and irisin
1. Introduction
Cholesterol is mainly composed of low-density lipoprotein (LDL), very-low-density lipopro-
tein (VLDL) and high-density lipoprotein (HDL). It plays a critical role in membrane biogen-
esis and steroid hormone biosynthesis. The disturbed plasma cholesterol is associated with 
many diseases, such as cardiovascular disease, diabetes and hepatic steatosis. Cholesterol 
is either uptaked exogenously from the diet or synthesized endogenously within cells. The 
liver is the major organ for cholesterol de novo synthesis which involves 19-step complex bio-
chemical process. The rate-limiting enzyme is 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) 
reductase. Sterol regulatory element-binding protein 1c (SREBP-1c) is the master regulator 
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of cholesterol by stimulating the transcription of LDL and HMG-CoA. LDL receptor (LDLr) 
is responsible for importing LDL from extracellular to intracellular environment for metabo-
lism. Cholesterol is the primary source for biogenesis of steroid hormones. In turn, many 
hormones exert critical effects on cholesterol synthesis or metabolism. This occurs through 
the direct effect of these hormones on regulation of the expression or activity of HMG-CoA 
reductase, SREBP-1c or LDLr. In this chapter, we will discuss the regulatory role of several 
interesting hormones in cholesterol metabolism.
2. Thyroid hormone
2.1. Thyroid hormone and thyroid hormone receptors
Thyroid hormones (THs) include thyroxine (T4) and triiodothyronine (T3). They are synthe-
sized and secreted by the thyroid gland. T4 is the major secreted hormone, while T3 has a higher 
affinity for TH receptors (TRs). T3 is considered as the active and more potent TH. T4 could 
be converted to T3 through a deiodination process catalyzed by deiodinases. TH regulates a 
number of biological functions including growth, development and metabolism in almost all 
tissues [1]. TH exerts these effects through binding to TRs which are expressed on different cells 
and tissues. TRs have two isoforms, TRα and TRβ, which are encoded by the THRA and THRB 
genes, respectively, in humans. Each TR isoform has several splice products, TRα1 (α2) and 
TRβ1 (β2). TRα1 and TRβ1 are ubiquitously expressed, while TRβ1 is the major TR existed in 
the liver. TRβ2 is expressed in the hypothalamus, the pituitary gland and the developing brain 
[2]. TRs are ligand-activated transcription factors, belonging to the family of nuclear recep-
tors (NRs). It can bind to DNA sequences called TH-responsive elements (TREs) together with 
the retinoid X receptor alpha (RXR-α). In the absence of TH, TRs bind with corepressors, e.g., 
nuclear receptor corepressor and silencing mediator for retinoid and thyroid hormone receptor 
(NCOR2), suppressing the transcriptional activity. In the presence of TH, the binding induces 
a conformational change of TRs, releasing the corepressors and recruiting several co-activators 
to enhance the transcriptional activity. Since TRs associate with corepressors without ligand 
binding, it could decrease the transcriptional activity of the target genes. Therefore, it should 
be cautious to compare the data from animal models in which TRs are genetically deleted with 
the models with low levels of circulating THs, such as hypothyroidism or thyroidectomy [3].
2.2. Role of TH in cholesterol metabolism
There is substantial evidence linking TH status with cholesterol or lipid metabolism. 
Thyroid dysfunction exerts an important effect on the cholesterol level. Hypothyroidism 
patients typically have elevated plasma cholesterol and increased lipid accumulation in the 
liver. TH supplement can normalize this lipid dysregulation. THs promote cholesterol syn-
thesis through inducing HMG-CoA reductase and farnesyl pyrophosphate gene expression 
[1]. THs markedly decrease the expression of apoB-100, the major protein of LDL, while 
increasing the expression of apo A-I, the major protein of HDL. In addition, THs increase 
LDLr gene expression. LDLr mediates the uptake of LDL from blood to the liver. Rat LDLr 
promoter contains two functional TREs. THs could directly bind to the TRE and upregulate 
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the LDLr gene expression [4]. THs may also regulate the clearance of circulating remnant 
lipoproteins. Hepatic low-density lipoprotein receptor-related protein 1 (LRP1) is a receptor 
for remnant lipoproteins. Hepatic LRP1 protein expression and function are reduced in the 
hypothyroidism mouse model. T3 supplement partially normalizes its protein expression 
level [5]. THs also promote the cholesterol elimination by increasing conversion and secre-
tion of cholesterol into bile acids. In this process, cholesterol 7α-hydroxylase (Cyp7A1), 
the enzyme in the cytochrome P450 family, is responsible for catalyzing the rate-limiting 
reaction in the degradation of cholesterol. Cyp7A1 is a direct TR target gene with TREs 
in its promoter region [6]. ATP-binding cassette (ABC) transporters G5 (ABCG5) and G8 
(ABCG8) form a heterodimer that limits intestinal absorption and facilitates biliary secre-
tion of cholesterol. Mice homozygous for disruption of Abcg5 demonstrate a significant 
reduction in basal biliary cholesterol secretion. T3 treatment does not increase the choles-
terol secretion in Abcg5−/− mice as in the wild-type control mice. This observation suggests 
that THs induce secretion of cholesterol, largely dependent on the ABCG5/G8 transporter 
complex [7]. THs also modulate gene expression via micro-RNAs. In a human hepatic cell 
line, THs decrease sterol O-acyltransferase 2 (SOAT2 or ACAT2), the enzyme crucial for the 
hepatic secretion of cholesterol esters, via miR-181d [8].
T3 also upregulates LDLr gene expression by activating the expression of the sterol regulatory 
element-binding protein-2 (SREBP-2) and scavenger receptor class B1 (SR-B1) [9]. Cholesteryl 
ester transfer protein (CETP) mediates the exchange of cholesteryl esters from HDL to the 
VLDL and from total triglyceride (TG) to the opposite direction. THs could increase the activ-
ity of CETP to influence HDL metabolism [10]. In addition, THs stimulate the lipoprotein 
lipase (LPL) and hepatic lipase (HL) levels, catabolizing the TG-rich lipoproteins.
2.3. Interaction with other transcription factors
In addition to the direct action on the cholesterol-related genes, TRs also cross talk with many 
nuclear receptors to regulate their transcriptions. It shares the same DNA-binding site (direct 
repeat 4) with liver X receptor (LXR). Activation of TRβ1 by T3 upregulates mouse LXRα, but 
not LXRβ, mRNA expression in the liver at the transcriptional level [11]. TRβ1 is the major TR 
mediating the TH effects on plasma cholesterol. ATP-binding cassette transporter A1 (ABCA1) 
is important for HDL assembly and transporting cholesterol back to the liver for excretion. TR 
forms a heterodimer with retinoid X receptor (RXR) and binds to the DR-4 element of ABCA1 
promoter, suppressing its transcription [12]. The apolipoprotein AV gene (APOA5) is a key 
determinant of the plasma triglyceride level. It affects the plasma TG level through promoting 
lipolysis of TG-rich lipoproteins and removal of their remnants [13]. TR-β mediates the effects 
of THs on the activation of APOA5 gene. Administration of TR-β-selective agonist increases 
apoAV and diminishes triglyceride levels [14]. In addition, TR-β may compete with LXR/
RXR heterodimers for binding to the DR-4 element in the CYP7A1 promoter [15]. TR-β but 
not TR-α KO mice completely lost the induction effects of T3 on Cyp7a1 gene, confirming the 
critical role of TR-β in mediating the TH effect on cholesterol metabolism [16].
Taken together, TH regulates the serum cholesterol level in multiple crucial steps including 
stimulating its hepatic synthesis, serum uptake and the intrahepatic conversion to bile acids. 
The physiological level of TH is essential for maintaining the cholesterol homeostasis.




It is well recognized that premenopausal females have better lipid profiles than males and 
are more protected from hypercholesterolemia-related diseases, such as cardiovascular dis-
eases. Lipid screening has found that premenopausal women are associated with a lower 
level of LDL cholesterol and a higher level of HDL cholesterol. After menopause, the gender 
difference of lipid profiles disappears, and women even have higher-level LDL compared to 
age-matched men [17]. Estrogen replacement therapy would improve lipoprotein profiles in 
postmenopausal women [18]. Sex hormones, especially estrogen, account for the gender dif-
ference of cholesterol profiles.
3.1. Estrogen and estrogen receptors
The predominant and most important biologically relevant form of estrogen is 17β-estradiol 
(E2). Both women and men produce E2 through aromatization of androgen. In premenopausal 
women, estrogen is mainly synthesized in the ovaries. While in postmenopausal women and 
men, it is primarily converted from testosterone by aromatase (encoded by CYP19 gene) in 
extragonadal tissues such as adipose tissue, adrenal glands, bones, etc. [19]. There are at least 
three types of estrogen receptors, ER-𝛼, ER-𝛽 and membrane-bound receptor G protein-cou-
pled ER (GPER, also known as GPR 30). ER-α and ER-β are the classic estrogen receptors and 
are mainly expressed in the cytosol. Upon estrogen binding, ER-α and ER-β form homo- or 
heterodimers and bind to estrogen response element (ERE) in the downstream target genes, 
to initiate or suppress the transcriptional activity. The GPER and membrane-associated ER-α 
and ER-β variants are expressed in the plasma membrane. They mainly exert actions via 
non-genomic signaling. This membrane-initiated signaling involves protein kinase A (PKA), 
protein kinase C (PKC) and mitogen-activated protein kinase (MAPK)/extracellular signal-
regulated protein kinase (ERK) signaling pathways [20–22].
3.2. Role of estrogens in cholesterol homeostasis
The influence and mechanism of estrogens on cholesterol metabolism have been investigated 
for a long time. Studies by Cypriani et al. in 1988 demonstrated that estrogens induced HMG-
CoA reductase and subsequent cholesterol synthesis in breast cancer cell line [4]. Later, it was 
found that HMG-CoA reductase gene promoter contains an estrogen-responsive element-like 
sequence at position-93 (termed Red-ERE). And, estrogen induction of HMG-CoA reductase 
gene is dependent on the Red-ERE. The induction activity of estrogens occurs in the breast 
cancer cells but not in hepatic cells, indicating differential regulation of HMG-CoA reductase 
by estrogens in a tissue-specific manner [23]. Aromatase is an enzyme responsible for the key 
step in the biosynthesis of estrogens. Aromatase knockout (ArKO) mice display increased 
intra-abdominal adipose tissue and lipid droplet accumulation in the liver. Total cholesterol 
and LDL are also elevated in these transgenes [24]. Supplement of estrogens in both ArKO 
mice and rats with ovariectomy (OVX) normalizes LDL and total cholesterol levels, confirm-
ing the important role of estrogens in the lipid homeostasis in both males and females [25]. 
Hormone replacement therapy (HRT) increases the expression of leucocyte ABCA1 gene, 
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which mediates the efflux of cholesterol to the HDL particles, leading to the subsequent 
increase in the HDL cholesterol level [26]. Estrogens thus play an important role in the modu-
lation of the total cholesterol level by reducing LDL and concurrently increasing HDL.
The beneficial role of estrogens on cholesterol metabolism is mediated through nuclear and extra-
nuclear ER-α and ER-β, as well as GPER. Genetic deletion of ER-α in mice results in upregulation 
of the genes involved in hepatic lipid biosynthesis and downregulation of the genes involved in 
lipid transport, indicating that estrogens act via ER-α to regulate lipid metabolism [27]. ER-α KO 
and ER-α/β double KO mice showed increased serum cholesterol and smaller LDL particles, but 
not in ER-β single KO mice [28]. Therefore, ER-α plays a more prominent role than ER-β. The 
roles of GPER in the regulation of metabolism are only beginning to emerge, which gains more 
attentions. GPER knockout mice exhibit impaired cholesterol homeostasis manifesting signifi-
cantly a higher LDL level but a normal HDL level, suggesting that GPER mainly regulates LDL 
metabolism [29]. And, human individuals with a hypofunctional GPER P16L allele are associated 
with elevated plasma LDL. In vitro study shows that activation of GPER by the agonist upregu-
lates hepatic LDLr expression [30]. The role of GPER signaling in cholesterol or metabolic con-
trol remains unclear and needs more further investigations [31]. In summary, estrogens protect 
against increases in the plasma cholesterol level mainly by activating ER-α and GPER.
3.3. Androgens
The human androgens include dehydroepiandrosterone, androstenedione, testosterone 
and dihydrotestosterone (DHT). Testosterone can be converted to DHT via 5α-reductase. 
Testosterones and DHT are active androgens, because they are the only androgens capable of 
binding to androgen receptors (ARs) to exert biological functions. AR is mainly expressed in 
the prostate, skeletal muscle, liver and central nervous system (CNS). Like ERs, AR is a mem-
ber of the steroid and nuclear receptor superfamily. Ligand binding induces a conformation 
change of AR, leading to recruitment of cofactor proteins and transcriptional machinery and 
subsequent regulation of the target genes’ transcription.
The effect of androgen on cholesterol is still not conclusive. Clinical studies show that andro-
gen deficiency, such as in old men, is associated with increased risks of dyslipidemia, higher 
serum cholesterol and LDL levels [32]. Another study has found that AR antagonists might 
be useful in the treatment of obesity in men [33]. In the animal studies, dihydrotestosterone 
(DHT) treatment in castrated obese mice decreases LDL secretion and increases the expres-
sion of hepatic scavenger receptor class B member 1 (SR-1B) which is important in regulating 
cholesterol uptake from HDL. It also decreases the enzyme cholesterol 7α-hydroxylase which 
participates in bile formation and cholesterol removal. In another study using an orchidecto-
mized Sprague–Dawley (SD) rat model, DHT treatment causes decreased lipid accumulation 
and cholesterol synthesis by increasing expression of carnitine palmitoyl transferase 1 and 
phosphorylation of HMG-CoA reductase via an AR-mediated pathway [34]. However, this 
finding in animals contradicts a clinical study showing that a single dose of testosterone injec-
tion increases the total cholesterol level by 15% through stimulating the hepatic expression of 
HMG-CoA reductase [35]. These contradictory results indicate a complex role of androgen on 
the cholesterol homeostasis in the liver.




4.1. Growth hormone and growth hormone receptors
Growth hormone (GH) is secreted by the somatotroph cells of the anterior pituitary gland 
under neural, hormonal and metabolic control. GH regulates postnatal growth, as well as 
lipid, glucose and energy metabolism. The molecular mechanism of GH action is relatively 
complicated. It affects metabolism through direct or indirect action via insulin-like growth 
factor-1 (IGF-1) or antagonism of insulin action. GH receptor (GHR) is a member of the cyto-
kine receptor superfamily. Upon binding to GH, GHR activates the cytoplasmic tyrosine 
kinase Janus kinase 2 (Jak2) and then recruits members of the signal transducer and activa-
tor of transcription (STAT) family of transcription factors. Phosphorylated STATs translocate 
into the nucleus and modulate the transcription of multiple target genes, including IGF-1, 
ALS and suppressor of cytokine signaling (SOCS) [36]. In addition to the Jak2/STAT signal-
ing pathway, GHR can activate the Src tyrosine kinase signaling pathway and cross talk with 
insulin and IGF-1 signaling pathways.
4.2. Role of GH in cholesterol and lipid metabolism
There exists a negative relationship between obesity and GH. Enormous evidence supports 
that GH alters lipid metabolism. Clinical studies have shown a significant association between 
lower serum GH levels and non-alcoholic fatty liver disease (NAFLD). Hypopituitary patients 
with GH deficiency are more prone to NAFLD than control subjects [37–39]. GH supplemen-
tation has been shown to improve the NAFLD and the metabolic dysfunction [40, 41]. In 
rodent studies, high-fat diet feeding and obesity suppress pulsatile GH secretion [42]. In turn, 
chronic GH treatment ameliorates hepatic lipid peroxidation and improves lipid metabolism 
in high-fat diet-fed rats [43].
Hypophysectomy is a surgery process in which the pituitary gland (hypophysis) is removed, 
leading to an impairment of GH secretion. This model is used for investigating the GH func-
tion in animals under pathophysiology conditions. Increase of hepatic LDLr and hypocholes-
terolemia induced by estrogens is completely attenuated in hypophysectomized rats. Only 
GH supplementation is able to restore this effect of hypophysectomy. Further, GH treatment 
on the gallstone patients stimulates the expression of hepatic LDLr by twofold, leading to 
subsequent decrease in serum cholesterol by 25%. This study indicates that GH secretion 
is critical for the control of plasma LDL levels in humans [44]. GH is also important for the 
synthesis of bile acids by maintaining the normal activity of cholesterol 7α-hydroxylase. 
Hypophysectomized rats show significantly reduced activities of HMG-CoA reductase and 
cholesterol 7α-hydroxylase and hence an inhibition of cholesterol and bile acid biosynthe-
sis. GH substitution restores the enzymatic activity of 7α-hydroxylase and increases the fecal 
excretion of bile acids [45]. Treatment of LDLr-deficient mice with GH reduces their elevated 
plasma cholesterol and triglyceride levels by stimulating the activities of HMG-CoA reduc-
tase and cholesterol 7α-hydroxylase [46]. GH thus regulates plasma lipoprotein levels and 
bile acid metabolism by altering hepatic LDLr expression and the enzymatic activity of cho-
lesterol 7α-hydroxylase, respectively.
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GHR is present in the liver and critical for the hepatic lipid metabolism. Laron dwarfism is 
a disorder characterized by an insensitivity to GH due to a genetic mutation of GHR. These 
male patients manifest NAFLD in adults [47]. Liver-specific deletion of GHR in mice leads 
to increased circulating free fatty acids and fatty liver as a result of increased synthesis and 
decreased efflux of triglyceride [48]. Binding of GH to GHR activates JAK2-STAT5 signaling 
pathway and modulates a number of target genes. Among these, altered expression of CD36, 
PPARγ and PGC1α/β, along with fatty acid synthase, lipoprotein lipase and very-low-density 
lipoprotein receptor (VLDLr) contributes to the hepatic lipid metabolism process [49, 50]. All 
these findings suggest that hepatic GH signaling is essential for the regulation of intrahepatic 
lipid and cholesterol metabolism.
5. Glucagon
Glucagon is a 29-aa peptide hormone secreted from the pancreatic islet alpha cells in response 
to low glucose. It is a well-known counter-regulatory hormone to insulin, mainly stimulating 
hepatic glucose production by increasing glycogenolysis and gluconeogenesis and concur-
rently inhibiting glycogen synthesis. Glucagon also affects hepatic cholesterol metabolism. 
The relationship between glucagon and cholesterol has been investigated since the 1950s 
[51]. The portacaval shunt surgery in a 6-year-old girl with the homozygous form of familial 
hypercholesterolemia disorder has been reported to significantly reduce LDL and cholesterol 
synthesis 5 months after surgery. This alteration is associated with a marked elevation of bile 
acids and the glucagon level, indicating that glucagon may improve hepatic lipid metabolism 
[52]. In the animal study, infusion of glucagon into the hyperlipidemic rat reduces circulating 
VLDL apoprotein and serum TG levels. It is due to the inhibition of incorporating amino acid 
into the apoprotein by glucagon [53]. Chronic glucagon administration in rats significantly 
reduces serum cholesterol and triglyceride levels but not in the liver. The internal secretion 
of cholesterol and cholesterol transformation into bile acids measured by an isotope balance 
method are strikingly increased, suggesting that glucagon stimulates cholesterol turnover rate 
[54]. Studies by Rudling et al. have found that injection of glucagon increases LDL binding to 
the LDLr in a dose-dependent manner and concomitantly decreases cholesterol and apoB/E in 
LDL and large HDL particles in rats. Moreover, the induction of LDLr by glucagon is not due 
to increased mRNA levels, indicating a novel posttranscriptional regulatory mechanism pres-
ent in the liver [55]. In humans, glucagon administration represses cholesterol 7α-hydroxylase 
(CYP7A1) mRNA expression by increasing the PKA phosphorylation of HNF4a and reducing 
its ability to bind with the CYP7A1 gene, thus inhibiting bile acid synthesis [56].
Glucagon receptor, encoded by the GCGR gene, is a seven-transmembrane protein and 
belongs to the class II guanine nucleotide-binding protein (G protein)-coupled receptor 
superfamily. They are abundantly expressed in the liver and kidney. In the liver, glucagon 
receptors are mainly located in hepatocytes, with a small number expressed on the surface of 
Kupffer cells [57]. Mice with a null mutation of the glucagon receptor (Gcgr−/−) display low 
blood glucose and markedly elevated the plasma LDL level. Serum total cholesterol and HDL 
are not significantly changed in Gcgr−/− mice [58]. Gcgr−/− mice are more prone to develop 
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hepatosteatosis following high-fat diet feeding [59]. Several glucagon receptor antagonists 
(GRA) have been developed to reduce hepatic glucose overproduction and improve the 
overall glycemic status. However, some GRAs including MK-0893 have been shown to dose-
dependently increase LDL in T2DM patients. In the rodent preclinical trial, blockade of gluca-
gon receptor using various GRAs elevates plasma LDL-c and total cholesterol. This is caused 
by increased cholesterol absorption instead of the change in cholesterol synthesis or secretion 
[60]. Taken together, these results suggest that glucagon plays a hypolipidemic effect through 
its glucagon receptors, making it an interesting and attractive pharmaceutical agent for the 
treatment of dyslipidemia and obesity.
6. Irisin
Irisin is a newly identified hormone encoded by the gene fibronectin type III domain-con-
taining protein 5 (FNDC5). It is secreted into the circulation as a cleaved protein product and 
induced by exercise [61]. Irisin is proposed to mediate the metabolic benefits of exercising 
by promoting the browning of subcutaneous adipose tissue, reducing visceral obesity and 
improving glucose and cholesterol metabolism. Circulating the irisin level is negatively asso-
ciated with fat mass, fasting glucose and dyslipidemia, as well as intrahepatic TG contents 
in humans [62, 63]. A higher baseline irisin level is associated with the metabolic benefits 
of diet-restricted treatment on human weight loss [64]. Lentivirus-mediated FNDC5 over-
expression or subcutaneous perfusion of irisin promotes lipolysis and reduces hyperlipid-
emia in obese mice [65]. Irisin is negatively associated with HDL cholesterol and large HDL 
particles in adults with higher cardiovascular risk [66]. In addition, the serum irisin level is 
significantly higher in the NAFLD patients than in normal subjects [67]. Elevation of saliva 
irisin is positively related to total cholesterol [68]. Subcutaneous infusion of irisin decreases 
body weight, plasma total, VLDL, LDL, HDL cholesterol in diet-induced obese mice. The 
hepatic levels of total and esterified cholesterol are also reduced. These alterations are associ-
ated with significant reduction in the expression of the genes important for cholesterol syn-
thesis, including Srebp2, HMG-CoA reductase (Hmgcr), the liver X receptor α (Lxrα, Nr1h3) 
and HMG CoA synthase (Hmgcs) in the liver and primary hepatocytes. Further experiments 
demonstrate that irisin inhibits cholesterol synthesis in hepatocytes through the activation of 
AMPK and SREBP2 [69]. As a novel hormone, evidence supporting the critical role of irisin 
in the regulation of cholesterol or lipid metabolism is still limited. More studies are needed to 
clarify the role of FNDC5/irisin in the lipid homeostasis under physiological and pathologi-
cal conditions.
7. Conclusion
Cholesterol balance is regulated at multiple steps, including the biosynthesis, uptake, intra-
cellular transport and conversion to bile acids for excretion. Hormones affect cholesterol 
biosynthesis and uptake by altering the transcription of genes critical for these biological 
processes (Table 1). Novel identified hormones are constantly added into the list implicated 
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in cholesterol balance process. Identification of hormonal receptor agonist/antagonist and 
understanding the hormonal regulatory mechanisms would help to identify potential effec-
tive and selective targets for the control of cholesterol dysfunction.
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